Navigation Links
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program
Date:6/28/2012

NEW YORK, June 28, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program

http://www.reportlinker.com/p0832795/Pricing-and-Reimbursement-in-Russia---Big-Pharma-Take-Advantage-of-Reimbursement-for-Costly-Drugs-Through-the-DLO's-Seven-Nosologies-Program.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program

Summary GBI Research, the leading business intelligence provider, has released its latest research "Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO's Seven Nosologies Program". It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Russia, with key data, information and analysis of the steps of the pricing and reimbursement process. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement in Russia due to the implementation of a new law "On Circulation of Drugs".

The scenario of pricing and reimbursement of drugs in Russia is in a dynamic phase. The government of Russia increased the funding of National Healthcare Project to improve the primary healthcare provided to Russians. Under the National Healthcare Project, improvement in primary healthcare, out-patient clinics and technology centers was done. The launch of the DLO (the acronym for Additional
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
2. Elsevier and Russias Skolkovo Foundation Sign Access Agreement to SciVerse Scopus and SciVal Funding
3. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
4. BHR Pharma Expands SyNAPSe® Trial into Thailand, China and Russia
5. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
6. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
7. Pharmaceuticals: Global Industry Almanac, MarketLine
8. Buyer Spend Activity and Procurement Behaviors and Strategies in the Pharmaceutical Industry - 2012-2013 : Survey Intelligence
9. Nature Made Selected As "Top Recommended Health Product" By U.S. News & World Report And Pharmacy Times
10. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
11. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Boehringer Ingelheim will contribute ... at the American Thoracic Society International Conference (ATS ... May 17 – 22. Data will ... the treatment of chronic obstructive pulmonary disease (COPD) ... as investigational compounds for asthma, idiopathic pulmonary fibrosis ...
(Date:5/17/2013)... PARIS , May 17, 2013  Sanofi (EURONEXT: ... the pivotal study, JAKARTA , examining ... its primary endpoint in both dose groups. The primary ... of spleen volume. Consistent with data reported in previous ... nausea and vomiting. Full results will be presented at ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... LONDON , March 17, 2010 Hikma Pharmaceuticals,today announced 2009 preliminary results with operating profits up 36% on the,back of a strong performance from its Middle East ... , ... ... ...
... 16 American pharmaceutical manufacturer Alpharma Inc. has agreed ... Act allegations in connection with the marketing of the morphine-based ... allegations that, between January 1, 2000 and ... induce them to promote or prescribe Kadian, and made misrepresentations ...
Cached Medicine Technology:Hikma 2009 Results Interviews With CEO and CFO 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 3
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... in a federal litigation now underway in U.S. District ... Case Management Order dated May 3rd, the Court has ... Nominee Pool to eight cases rather than four. The ... scheduled for Thursday, May 23rd. (In re: Actos Product ...
(Date:5/19/2013)... City, Utah (PRWEB) May 19, 2013 ... information on small business health insurance . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... start-ups, and the self-employed intrinsically know the value ...
(Date:5/19/2013)... According to a new market research report ... 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), Surveillance, ... IS, Infrared, X-Ray) And Geography" published by MarketsandMarkets, ... billion in 2012 and is expected to reach ... of 3.84% from 2013 to 2018. In terms ...
(Date:5/19/2013)... 19, 2013 These molecular diagnostics ... UK, Spain, Japan, Italy, Germany and France:, ... diagnostics laboratory practice, as well as key economic, ... market impact during the next five years. , ... biochip technologies, test formats, detection methodologies, trends in ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... 31, 2008) Real-world use of a novel drug-eluting ... good clinical outcomes, according to one-year data from a ... focused on the sirolimus-eluting Excel stent, are being reported ... SCAI Annual Scientific Sessions in Partnership with ACC i2 ...
... 31, 2008) A large community-based registry of patients ... how long patients with complex coronary artery disease typically ... drug that prevents unwanted blood clots; why they stop ... decision. , The new data from the MATRIX ...
... Percutaneous coronary intervention (PCI) may be a reasonable ... the left main coronary artery, according to a study ... when stents and bypass surgery were used to restore ... were treated with stenting were more likely to need ...
... refined salt prompt consumers, food industry to consider ... benefits of natural sea ... chemicals over a dinner plate - yet that,s exactly what millions,of ... food,with refined table salt, says Mark Zoske, co-founder of SaltWorks, Inc.,( ...
... Teleconference Tuesday, April 1, 2008 at 9:30 AM EDT, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... fiscal year, ended December 31, 2007., Key ... System was formally unveiled to market at ...
... Pharmaceutical Holdings, Inc. (Amex: KUN ) ("China ... research, development, manufacture,and marketing of pharmaceutical, nutritional supplement ... ("PRC"), today announced it will,conduct a conference call ... 2008, to,discuss the Company,s financial results for the ...
Cached Medicine News:Health News:Registry unveils 'real-world' data on novel excel stent 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 3Health News:Study finds support for PCI in unprotected left main disease 2Health News:Study finds support for PCI in unprotected left main disease 3Health News:SaltWorks, Inc. Advises Table Salt Alternatives 2Health News:Milestone Scientific Announces 2007 Year-End Results 2Health News:Milestone Scientific Announces 2007 Year-End Results 3Health News:Milestone Scientific Announces 2007 Year-End Results 4Health News:Milestone Scientific Announces 2007 Year-End Results 5Health News:Milestone Scientific Announces 2007 Year-End Results 6Health News:Milestone Scientific Announces 2007 Year-End Results 7Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3
7 mm strong curved blade. Round handle....
3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
5 mm diameter blade. Angled 45 degrees. Hexagonal handle....
0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
Medicine Products: